Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-label Study to Investigate the Efficacy and Safety of PTK787/ZK 222584 Orally Administered Once Daily or Twice Daily at 1250 mg as Second-line Monotherapy in Patients With Stage IIIB or Stage IV Non-small-cell Lung Cancer (NSCLC)

NCT00160043 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00160043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00160043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-label Study to Investigate the Efficacy and Safety of PTK787/ZK 222584 Orally Administered Once Daily or Twice Daily at 1250 mg as Second-line Monotherapy in Patients With Stage IIIB or Stage IV Non-small-cell Lung Cancer (NSCLC)
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
November 30, 2008
Enrollment
112 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer